Hudson Bay Capital Management
RVNC

Hudson Bay Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Hudson Bay Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-414,310
Closed -$1.26M – 1543
2024
Q4 		$1.26M Buy
414,310
+264,310
+176% +$1.15M ﹤0.01% 715
2024
Q3 		$779K Buy
+150,000
New +$745K ﹤0.01% 699

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Hudson Bay Capital Management's RVNC Position: Q1 2025 in Review

Hudson Bay Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 414,310 shares — an estimated $1.26M sold.

Hudson Bay Capital Management first reported a position in RVNC in Q3 2024 and held it in 2 quarters. The position peaked at $1.26M in Q4 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Hudson Bay Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Hudson Bay Capital Management sold 414,310 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $1.26M.
  • Hudson Bay Capital Management first reported a position in Revance Therapeutics, Inc. in Q3 2024 and held it in 2 quarters.
  • Hudson Bay Capital Management's Revance Therapeutics, Inc. position peaked at $1.26M in Q4 2024.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Hudson Bay Capital Management's 13F filing for Q1 2025, filed 14 May 2025.